

Current HCV epidemiology in Germany

PHC 2018 - www.aphc.info

- Robert Koch Institute, Berlin, Germany
- German Ministry of Health
- German Federal Statistical Office
- Eurotransplant
- Polaris Observatory (JCM The John Martin Foundation, CDA Foundation)

Current situation of hepatitis C in Germany


- Prevalence 0.3-0.5%
 - Diagnosed and viremic in 2012 estimated number N=160,000
- Total number of patients in 2017: 200,000 (estimate)
- New cases reported
 - 2015 n=4,913
 - 2016: n= 4,368
- Mortality: unknown (estimate N=1,700 in 2016)
- Number of liver transplantations (total in 2016: 888 + 50 LRLT)
 - 2016: N=46 (14 with HCC)
 - 2017: N=24 (12 with HCC)

Current treatment situation of hepatitis C in Germany

- Total number of patients treated by DAAs so far: N=55,000 (plus appr. 35,000 patients with DAA triple regimen in 2011-2013)
- Total number of patients treated by IFNa-free DAA regimens in
 - 2014: N=7,000
 - 2015: N=20,100
 - 2016 N=13,200
 - 2017 N=12,000-13,000

Current treatment situation of hepatitis C in Germany

Persons per month on DAA treatment



Current resources and programs for HCV

- Current resources provided by Health Authorities (amount in euros/year)
 - **No treatment restrictions**
- DAAs available: all DAAs licensed (except Asunaprevir)
(Daclatasvir, Simeprevir and 3D not any more on the market)

Current resources and programs for HCV

- DAA treatment costs per year
 - 2014: 664 million €
 - 2015: 1.3 billion €
 - 2016: 830 million €

Current programs for HCV

- Program for screening:
 - no national strategy
- Program to improve access to treatment :
 - no national strategy

Future actions planned

- German Ministry of Health strategy paper to reduce HIV, HBV, HCV and sexually transmitted infection
- Federal states have not implemented any elimination strategy
- No elimination goals specified by the ministry of health
- Some local/ federal state-initiated projects exist
- To improve screening
 - PWIDs, prisons (test and linkage to care), check-up35 2.0
- To facilitate access to treatment
 - linkage to care projects also evaluating point-of-care tests
- Future drugs available: No
- Other major action: No